Rifaximin, Microbiota Biology, and Hepatic Encephalopathy

Rifaximin is beneficial in the treatment of minimal hepatic encephalopathy (MHE). Kang et al. (Clin Transl Gastroenterol 7: e187; doi:10.1038/ctg.2016.44) investigated the effects of rifaximin in a mouse model of MHE-associated microbiota without concomitant liver disease. In addition to some impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Peleman, Cedric, Camilleri, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288587/
https://www.ncbi.nlm.nih.gov/pubmed/27711069
http://dx.doi.org/10.1038/ctg.2016.52

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288587/
https://www.ncbi.nlm.nih.gov/pubmed/27711069
http://dx.doi.org/10.1038/ctg.2016.52

Ejemplares similares